Individually dosed omalizumab facilitates peanut oral immunotherapy in peanut allergic adolescents

Background: Peanut oral immunotherapy (pOIT) has showed good short-term outcomes, but allergic reactions may prevent effective up-dosing and is a major cause of stopping OIT. In placebo-controlled ...